Scientists are testing Zoloft to treat Ebola

63.64% credibility
 
Related

Japan s Cat Island Asks Internet For Food, Gets More Than They Can Store

Stuff
1054 points

The schoolboy, 16, who will live with a Russian porn star in a hotel for a month

Stuff
4532 points



Most recent

Vigilancia en salud pública en Colombia: el ranking del INS que alerta sobre próximos brotes

Salud
6 points

El impacto del empleo en el desarrollo productivo del sur del conurbano

Hablemos de eso
6 points

¿Cómo encontrar el equilibrio laboral y optimizar la retención del talento?

Familia sana
16 points

El valor de escuchar a quienes ya han dado todo

Enrique TF
14 points

Salir de la zona de confort: La clave para desarrollar las habilidades que el mercado laboral busca

Hablemos de eso
10 points

De corregir a preservar: así avanza la tecnología de bioestimulación para la longevidad de la piel

Salud
26 points

Cómo las experiencias compartidas transforman los equipos de trabajo

Hablemos de eso
14 points

Networking en Perú: claves para la empleabilidad y el crecimiento profesional

Hablemos de eso
10 points

Cuando la sinrazón se sienta en el poder

Enrique TF
10 points

Aceptar la declaración sugerida sin revisar puede costarle sanciones de hasta el 200 %

Economía
18 points
SHARE
TWEET
When treated with the prescription drugs Zoloft and Vascor, mice infected with Ebola survived.

Scientists are testing Zoloft to treat Ebola

The new study was small and preliminary, but if the drugs prove effective in humans—a finding still years away—it could mean new treatments for the deadly disease.

When researchers treated 10 mice infected with Ebola with Vascor (bepridil), customarily used to control blood pressure in heart patients, all the mice survived the often-deadly virus. When 10 mice were treated with the antidepressant Zoloft (sertraline), seven survived.The next step, will be to test the drugs in guinea pigs and monkeys, says immunologist Gene Olinger.

Olinger is associate director for maximum containment training at Boston University’s National Emerging Infectious Diseases Laboratory (NEIDL) and an adjunct associate professor of infectious diseases. The drug analysis was done at his lab in Maryland, where he works as a contractor with the National Institutes of Health. NEIDL is awaiting approval for Biosafety Level 4 research, which would include on-site, live-virus Ebola studies.

‘DO SOMETHING QUICKLY’
Ebola has killed more than 11,000 Africans in an ongoing outbreak that began in December 2013. Olinger’s work with Ebola and other viral hemorrhagic fevers (VHF) began in 2004, when he was a civilian employee with the Army.

“We started to develop a drug screen using a live virus” that might find effective therapies, Olinger says. Given the time and expense—and failure rate—of developing new drugs, “I was tasked to find a way to do something quickly.”

Olinger says he thought it made sense to screen existing Food and Drug Administration–approved drugs, not just for the time saved, but because “the repurposing approach has been used in infectious diseases before.”

He cites two prominent examples: Viagra was originally a heart treatment drug before its effectiveness against erectile dysfunction was discovered, and thalidomide—used for nausea in pregnant women until it was found to cause birth defects—today is “a very good cancer drug.”

DRUG COCKTAIL
Researchers screened 2,600 drugs, representing 90 percent of the FDA-approved pharmaceutical library. Of those screened, 80, including antihistamines and treatments for breast cancer, heart disease, and depression, appeared to have some effectiveness against Ebola. The drugs were put in dishes along with cells infected with the disease, to see if the drugs might block the virus. Those that looked most effective were tested then in mice.

The effective drugs appear to work by damming up cellular pathways through which Ebola enters. “We do know there are synergistic combinations that are possible,” he says, meaning that an ultimate therapy might involve a cocktail of several drugs, similar to the way HIV is treated.

The findings, published in the journal Science Translational Medicine, even surprised Olinger.

“I was shocked at the breadth of the type of drugs that had an impact,” he says, such as drugs blocking estrogen receptors in the cells. “Why would a virus need an estrogen receptor? I could see years of research just on a basic level just off that one finding.”

Fuente: www.futurity.org
SHARE
TWEET
To comment you must log in with your account or sign up!
Featured content